Seattle Genetics

TIVDAK

Manufacturer:

Seattle Genetics

Tivdak HCPCS:

J9273

HCPCS Code Descriptor:

Injection, tisotumab vedotin-tftv, 1 mg

Category:

J Code

Tivdak NDCs:

51144-0003-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Tivdak:

TIVDAK is an Oncology drug manufactured by Seattle Genetics and administered via the Intravenous route of administration. The J Code: J9273 is aligned to the drug TIVDAK.

ACCESS PRICING AND MORE BY REGISTERING

J9273 Added Date:

April 1, 2022

J9273 Effective Date:

April 1, 2022

J9273 Termination Date:

HCPCS Active

Tivdak billing and coding information can be found through Seattle Genetics at the link below:
Tivdak patient assistance information can be found through The Seagen Secure Patient Assistance Program at the URL: https://www.seagensecure.com/patient/tivdak
TIVDAK prescribing information can be found at the link below:
Information regarding TIVDAK’s side effects can be found at MedlinePlus